PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab

We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor exhibited extensive infiltration by CD8+ cytotoxic T lymphocytes, low-to-moderate mutational burden, no PD-L1 staining by commercially availabl...

Full description

Bibliographic Details
Main Authors: Saby George, Antonios Papanicolau-Sengos, Felicia L. Lenzo, Jeffrey M. Conroy, Mary Nesline, Sarabjot Pabla, Sean T. Glenn, Blake Burgher, Jonathan Andreas, Vincent Giamo, Moachun Qin, Yirong Wang, Lorenzo Galluzzi, Carl Morrison
Format: Article
Language:English
Published: Taylor & Francis Group 2018-12-01
Series:OncoImmunology
Subjects:
22c3 assay
adora2a
atezolizumab
immunohistochemistry
pd-1
sp142 assay
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1460298

Internet

http://dx.doi.org/10.1080/2162402X.2018.1460298

Similar Items